These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 33942222

  • 1. Gene mutations in acute promyelocytic leukemia early death in patients treated with arsenic trioxide alone.
    Chen X, Fan S, Zhao Y, Zhou J.
    Clin Transl Oncol; 2021 Oct; 23(10):2171-2180. PubMed ID: 33942222
    [Abstract] [Full Text] [Related]

  • 2. Comparative analysis of causes and predictors of early death in elderly and young patients with acute promyelocytic leukemia treated with arsenic trioxide.
    Jin B, Zhang Y, Hou W, Cao F, Lu M, Yang H, Tian X, Wang Y, Hou J, Fu J, Li H, Zhou J.
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):485-492. PubMed ID: 31686248
    [Abstract] [Full Text] [Related]

  • 3. Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia.
    Yang S, Ma R, Yuan X, Jiang L, Shi J, Yang J, Lei P, Zang Y, Chen X, Zhang Y, Liu Z, Guo J, Zhang L, Zhu X, Zhu Z.
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e382-e391. PubMed ID: 32336675
    [Abstract] [Full Text] [Related]

  • 4. Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide.
    Shen Y, Fu YK, Zhu YM, Lou YJ, Gu ZH, Shi JY, Chen B, Chen C, Zhu HH, Hu J, Zhao WL, Mi JQ, Chen L, Zhu HM, Shen ZX, Jin J, Wang ZY, Li JM, Chen Z, Chen SJ.
    EBioMedicine; 2015 Jun; 2(6):563-71. PubMed ID: 26285909
    [Abstract] [Full Text] [Related]

  • 5. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.
    Poiré X, Moser BK, Gallagher RE, Laumann K, Bloomfield CD, Powell BL, Koval G, Gulati K, Holowka N, Larson RA, Tallman MS, Appelbaum FR, Sher D, Willman C, Paietta E, Stock W.
    Leuk Lymphoma; 2014 Jul; 55(7):1523-32. PubMed ID: 24160850
    [Abstract] [Full Text] [Related]

  • 6. Factors affecting thrombohemorrhagic early death in patients with acute promyelocytic leukemia treated with arsenic trioxide alone.
    Hou W, Zhang Y, Jin B, Cao W, Lu M, Yan L, Yang H, Tian X, Hou J, Fu J, Zhao H, Li H, Zhou J.
    Blood Cells Mol Dis; 2019 Nov; 79():102351. PubMed ID: 31400712
    [Abstract] [Full Text] [Related]

  • 7. Long-term follow-up of children with acute promyelocytic leukemia treated with Beijing Children's Hospital APL 2005 protocol (BCH-APL 2005).
    Zhang Y, Wang L, Zhang R, Qi P, Xie J, Shi H, Lin W, Wu Y, Yu J, Fan J, Feng G, Zheng H, Wu M.
    Pediatr Hematol Oncol; 2019 Oct; 36(7):399-409. PubMed ID: 31530209
    [Abstract] [Full Text] [Related]

  • 8. Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy.
    Abla O, Ribeiro RC, Testi AM, Montesinos P, Creutzig U, Sung L, Di Giuseppe G, Stephens D, Feusner JH, Powell BL, Hasle H, Kaspers GJL, Dalla-Pozza L, Lassaletta A, Tallman MS, Locatelli F, Reinhardt D, Lo-Coco F, Hitzler J, Sanz MA.
    Ann Hematol; 2017 Sep; 96(9):1449-1456. PubMed ID: 28597167
    [Abstract] [Full Text] [Related]

  • 9. Effects of peripheral blood leukocyte count and tumor necrosis factor-alpha on early death in acute promyelocytic leukemia.
    Wen J, Xu F, Zhou Q, Shi L, Liu Y, Yue J, Zhang Y, Liang X.
    BMC Cancer; 2023 Jan 07; 23(1):27. PubMed ID: 36611025
    [Abstract] [Full Text] [Related]

  • 10. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
    Ghavamzadeh A, Jalili M, Rostami S, Yaghmaie M, Aliabadi LS, Mousavi SA, Vaezi M, Fumani HK, Jahani M, Alimoghaddam K.
    Leuk Res; 2018 Mar 07; 66():85-88. PubMed ID: 29407588
    [Abstract] [Full Text] [Related]

  • 11. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
    Zhang X, Zhang H, Chen L, Wang M, Xi J, Liu X, Xie M, Li D, Gulati ES, Gong S, Wang H.
    Trials; 2018 Sep 05; 19(1):476. PubMed ID: 30185214
    [Abstract] [Full Text] [Related]

  • 12. Difference in causes and prognostic factors of early death between cohorts with de novo and relapsed acute promyelocytic leukemia.
    Zhao H, Zhao Y, Zhang Y, Hou J, Yang H, Cao F, Yang Y, Hou W, Sun J, Jin B, Fu J, Li H, Wang P, Ge F, Zhou J.
    Ann Hematol; 2018 Mar 05; 97(3):409-416. PubMed ID: 29289982
    [Abstract] [Full Text] [Related]

  • 13. Toward Candidate Proteomic Biomarkers in Clinical Monitoring of Acute Promyelocytic Leukemia Treatment with Arsenic Trioxide.
    Cao F, Li X, Yang Y, Fang H, Qu H, Chang N, Ma Q, Cao W, Zhou J, Wang W.
    OMICS; 2019 Feb 05; 23(2):119-130. PubMed ID: 30767729
    [Abstract] [Full Text] [Related]

  • 14. FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group.
    Kutny MA, Moser BK, Laumann K, Feusner JH, Gamis A, Gregory J, Larson RA, Powell BL, Stock W, Willman CL, Woods WG, Meshinchi S.
    Pediatr Blood Cancer; 2012 Oct 05; 59(4):662-7. PubMed ID: 22378655
    [Abstract] [Full Text] [Related]

  • 15. Plasma cell-free DNA in patients with acute promyelocytic leukaemia treated with arsenic trioxide.
    Fujihara J, Nishimoto N, Takeshita H.
    Ann Clin Biochem; 2024 Jul 05; 61(4):248-254. PubMed ID: 37944991
    [Abstract] [Full Text] [Related]

  • 16. Analysis of gamma-glutamyltransferase in acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
    Sui M, Wei H, Zhang Q, Xiu R, Shen X, Zhang Z, Zhou J.
    Hematology; 2021 Dec 05; 26(1):58-64. PubMed ID: 33402059
    [Abstract] [Full Text] [Related]

  • 17. Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia.
    Zhang Y, Wu S, Luo D, Zhou J, Li D.
    PLoS One; 2016 Dec 05; 11(1):e0147545. PubMed ID: 26812490
    [Abstract] [Full Text] [Related]

  • 18. Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide.
    Hou J, Wang S, Zhang Y, Fan D, Li H, Yang Y, Ge F, Hou W, Fu J, Wang P, Zhao H, Sun J, Yang K, Zhou J, Li X.
    Ann Hematol; 2017 Dec 05; 96(12):2005-2013. PubMed ID: 28940056
    [Abstract] [Full Text] [Related]

  • 19. Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy.
    Lou Y, Ma Y, Suo S, Ni W, Wang Y, Pan H, Tong H, Qian W, Meng H, Mai W, Huang J, Yu W, Wei J, Mao L, Jin J.
    Leuk Res; 2015 Sep 05; 39(9):938-44. PubMed ID: 26183877
    [Abstract] [Full Text] [Related]

  • 20. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
    Testa U, Lo-Coco F.
    Ann Hematol; 2016 Apr 05; 95(5):673-80. PubMed ID: 26920716
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.